The BRCA-P Study is a “randomized trial,” meaning that women who consent to join will be randomly assigned by computer to receive either denosumab or a placebo (inactive substance) as a small injection under the skin every 6 months for the 5 years of the study. Neither the woman nor study staff will know which substance she is receiving, but it will be the same one throughout the study. See more details about study participation.
BRCA-P Study recruitment
The BRCA-P Study is enrolling nearly 3,000 women with a BRCA1 mutation from around the world. The study is open in more than 30 sites in the United States, as well as sites in Austria, Australia, Germany, Israel, Spain, and the United Kingdom.
We welcome and hope all eligible women will consider joining us, regardless of race, religion, color, or any other non-medical factor.
Your participation will help advance the latest breast cancer research for future generations! Join us to help make a difference.